Intrexon (NASDAQ: XON) is one of 32 public companies in the “Commercial physical research” industry, but how does it contrast to its rivals? We will compare Intrexon to related companies based on the strength of its earnings, institutional ownership, risk, profitability, analyst recommendations, dividends and valuation.

Insider and Institutional Ownership

75.1% of Intrexon shares are owned by institutional investors. Comparatively, 46.3% of shares of all “Commercial physical research” companies are owned by institutional investors. 48.2% of Intrexon shares are owned by company insiders. Comparatively, 17.1% of shares of all “Commercial physical research” companies are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Analyst Recommendations

This is a summary of current ratings and price targets for Intrexon and its rivals, as provided by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Intrexon 1 1 2 0 2.25
Intrexon Competitors 156 692 1492 68 2.61

Intrexon currently has a consensus price target of $33.50, indicating a potential upside of 614.29%. As a group, “Commercial physical research” companies have a potential upside of 17.67%. Given Intrexon’s higher probable upside, research analysts plainly believe Intrexon is more favorable than its rivals.

Valuation and Earnings

This table compares Intrexon and its rivals top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Intrexon $160.57 million -$509.34 million -3.42
Intrexon Competitors $744.96 million $42.30 million 12.81

Intrexon’s rivals have higher revenue and earnings than Intrexon. Intrexon is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.


This table compares Intrexon and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Intrexon -363.14% -26.52% -15.07%
Intrexon Competitors -264.33% -19.33% -10.94%

Risk and Volatility

Intrexon has a beta of 2.18, suggesting that its stock price is 118% more volatile than the S&P 500. Comparatively, Intrexon’s rivals have a beta of 3.95, suggesting that their average stock price is 295% more volatile than the S&P 500.


Intrexon rivals beat Intrexon on 10 of the 13 factors compared.

Intrexon Company Profile

Intrexon Corporation operates in the synthetic biology field in the United States. The company, through a suite of proprietary and complementary technologies, designs, builds, and regulates gene programs, which are DNA sequences that consist of key genetic components. Its technologies include UltraVector gene design and fabrication platform, and its associated library of modular DNA components; Cell Systems Informatics; RheoSwitch inducible gene switch; AttSite Recombinases; Protein Engineering; Laser-Enabled Analysis and Processing; and ActoBiotics and AdenoVerse technology platforms. The company also provides reproductive technologies and other genetic processes to cattle breeders and producers; biological insect control solutions; technologies for non-browning apple without the use of any flavor-altering chemical or antioxidant additives; commercial aquaculture products; genetic preservation and cloning technologies; genetically engineered swine for medical and genetic research; and artwork, children's toys, and novelty goods that are derived from living organisms or enabled by synthetic biology. It serves health, food, energy, environment, and consumer markets. Intrexon Corporation has collaboration and license agreements with ZIOPHARM Oncology, Inc.; Oragenics, Inc.; Fibrocell Science, Inc.; Genopaver, LLC; S & I Ophthalmic, LLC; OvaXon, LLC; Intrexon Energy Partners, LLC; Persea Bio, LLC; Ares Trading S.A.; Intrexon Energy Partners II, LLC; Intrexon T1D Partners, LLC; AquaBounty Technologies, Inc.; Thrive Agrobiotics, Inc.; Exotech Bio, Inc.; Relieve Genetics, Inc.; AD Skincare, Inc.; Genten Therapeutics, Inc.; and CRS Bio, Inc. The company was formerly known as Genomatix Ltd. and changed its name to Intrexon Corporation in 2005. Intrexon Corporation was founded in 1998 and is based in Germantown, Maryland.

Receive News & Ratings for Intrexon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intrexon and related companies with's FREE daily email newsletter.